Cargando…

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers

BACKGROUND: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) including abiraterone. The relationship between PTEN loss and docetaxel sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rescigno, Pasquale, Lorente, David, Dolling, David, Ferraldeschi, Roberta, Rodrigues, Daniel Nava, Riisnaes, Ruth, Miranda, Susana, Bianchini, Diletta, Zafeiriou, Zafeiris, Sideris, Spyridon, Ferreira, Ana, Figueiredo, Ines, Sumanasuriya, Semini, Mateo, Joaquin, Perez-Lopez, Raquel, Sharp, Adam, Tunariu, Nina, de Bono, Johann S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995869/ https://www.ncbi.nlm.nih.gov/pubmed/29911685 http://dx.doi.org/10.1016/j.euo.2018.02.006

Ejemplares similares

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
por: Zafeiriou, Zafeiris, et al.
Publicado: (2019)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
por: Paschalis, Alec, et al.
Publicado: (2019)

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital
por: Bianchini, Diletta, et al.
Publicado: (2017)

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016)

Genomics of lethal prostate cancer at diagnosis and castration resistance
por: Mateo, Joaquin, et al.
Publicado: (2020)

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents
por: Crespo, M, et al.
Publicado: (2015)

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
por: Li, Xiangyi, et al.
Publicado: (2018)

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
por: Mehra, Niven, et al.
Publicado: (2018)

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
por: Lozano, Rebeca, et al.
Publicado: (2021)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

HER3 Is an Actionable Target in Advanced Prostate Cancer
por: Gil, Veronica, et al.
Publicado: (2021)

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
por: Lorente, D, et al.
Publicado: (2014)

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
por: Nava Rodrigues, Daniel, et al.
Publicado: (2018)

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
por: Kolinsky, M.P., et al.
Publicado: (2020)

Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
por: Bhalla, Ritu, et al.
Publicado: (2013)

Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG
por: Silva, Maria P., et al.
Publicado: (2016)

Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort
por: Morais, C.E., et al.
Publicado: (2019)

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
por: Bianchini, D, et al.
Publicado: (2013)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
por: Sumanasuriya, Semini, et al.
Publicado: (2021)

Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features
por: Perez-Lopez, Raquel, et al.
Publicado: (2018)

Application of Liquid Biopsies in Cancer Targeted Therapy
por: Sumanasuriya, S, et al.
Publicado: (2017)

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
por: Reid, A H M, et al.
Publicado: (2010)

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers
por: Burdelski, Christoph, et al.
Publicado: (2015)

Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer
por: NOH, BYEONG-JOO, et al.
Publicado: (2016)

Correlations of PTEN and ERG Immunoexpression in Prostate Carcinoma and Lesions Related to Its Natural History: Clinical Perspectives
por: Voulgari, Olga, et al.
Publicado: (2023)

Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer
por: Song, Wan, et al.
Publicado: (2016)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
por: Omlin, A, et al.
Publicado: (2013)

Reply: ‘Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
por: Omlin, A, et al.
Publicado: (2014)

Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer
por: Kim, Sung Han, et al.
Publicado: (2015)

Regulation of ERG3, ERG6, and ERG11 Genes in Antifungal-Resistant isolates of Candida parapsilosis
por: Lotfali, Ensieh, et al.
Publicado: (2017)

Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway
por: Zhou, Wenhao, et al.
Publicado: (2020)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
por: Carreira, Suzanne, et al.
Publicado: (2021)

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
por: Furusato, B, et al.
Publicado: (2010)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
por: Collins, Dearbhaile Catherine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kfdnjcv1cni1l75hg9ri9rrlbq